Literature DB >> 20438539

Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?

Georges Ouellet1, Héloïse Cardinal, Marjolaine Mailhot, Louis-Georges Ste-Marie, Louise Roy.   

Abstract

There is no guideline regarding the concomitant or distant administration of sevelamer and calcium carbonate. Our aim was to determine whether serum phosphate varied when sevelamer and calcium carbonate were administered concomitantly in comparison to administration at separate meals. Fourteen chronic hemodialysis patients were enrolled in this cross-over, randomized trial. Each subject underwent two four-week study periods. During the "concomitant" period, subjects were instructed to take both sevelamer and calcium carbonate together at each meal, whereas in the "separate" period, they were required to take them at separate meals. The order of the "concomitant" and "separate" periods was randomized. Phosphate-binding agents were stopped for a one-week washout period before each study period. The total dose of sevelamer and calcium carbonate for each subject remained the same for the whole duration of the study and had been determined according to their usual dose of phosphate binders. Patients were instructed to keep their usual eating habits constant and a nutritionist evaluated the daily phosphate intake three times per week. Dialysis parameters were kept constant. Pre-dialysis serum phosphate, calcium, bicarbonate, and albumin were measured at the end of each week. The average daily dietary phosphate intake remained unchanged throughout the study. At the end of the two study periods there was no significant difference in serum phosphate (1.50 +/- 0.46 mmol/L in the "concomitant" period vs. 1.51 +/- 0.31 mmol/L in the "separate" period, P = 0.97), calcium (2.26 +/- 0.19 mmol/L in the "concomitant" period vs. 2.27 +/- 0.15 mmol/L in the "separate" period, P = 0.64), calcium x phosphate product (3.36 +/- 0.94 mmol(2)/L(2) in the "concomitant" period vs. 3.41 +/- 0.71 mmol(2)/L(2) in the "separate" period, P = 0.84) and bicarbonate levels (21.5 +/- 3.3 mmol/L for the "concomitant" period vs. 21.6 +/- 3.1 mmol/L for the "separate" period, P = 0.81). Our results show that simultaneous administration of calcium carbonate and sevelamer does not decrease phosphate-binding capacity. Hence, patients can choose to take their phosphate binders concomitantly or at separate meals, according to their preference.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20438539     DOI: 10.1111/j.1744-9987.2009.00748.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  5 in total

Review 1.  Hyperphosphataemia: treatment options.

Authors:  Fabio Malberti
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

2.  Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).

Authors:  Marinella Ruospo; Suetonia C Palmer; Patrizia Natale; Jonathan C Craig; Mariacristina Vecchio; Grahame J Elder; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2018-08-22

Review 3.  The demise of calcium-based phosphate binders-is this appropriate for children?

Authors:  Lesley Rees; Rukshana Shroff
Journal:  Pediatr Nephrol       Date:  2014-12-28       Impact factor: 3.714

4.  Use of Phosphate Binders in End-Stage Renal Disease: An Experience From a Secondary Care Hospital in United Arab Emirates.

Authors:  Syed Arman Rabbani; Sathvik B Sridhar; Padma G M Rao; Martin T Kurian; Basset E Essawy
Journal:  J Pharm Bioallied Sci       Date:  2019 Apr-Jun

5.  A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study.

Authors:  Atsushi Yaguchi; Kenji Akahane; Kumi Tsuchioka; Saori Yonekubo; Shota Yamamoto; Yasuaki Tamai; Satoshi Tatemichi; Hiroo Takeda
Journal:  BMC Nephrol       Date:  2019-12-12       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.